Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib

Authors: Costa, R., Costa, R.B., Talamantes, Sarah M., Helenowski, Irene, Peterson, Jonna, Kaplan, Jason, Carneiro, B.A., Giles, Francis J., Gradishar, W.J.

Source: In The Breast October 2017 35:1-7

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis

Authors: Costa, R., Gill, N., Rademaker, A.W., Carneiro, B.A., Chae, Y.K., Kumthekar, P., Gradishar, W.J., Kurzrock, R., Giles, F.J.

Source: In Cancer Treatment Reviews April 2017 55:10-15

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives

Authors: Costa, R. ^*, Carneiro, B.A., Wainwright, D.A., Santa-Maria, C.A., Kumthekar, P., Chae, Y.K., Gradishar, W.J., Cristofanilli, M., Giles, F.J.

Source: In Annals of Oncology January 2017 28(1):44-56

188P IPH5201 as monotherapy or in combination with durvalumab (D) in advanced solid tumours

Authors: Imbimbo, M., Hollebecque, A., Italiano, A., McKean, M., Macarulla, T., Castanon Alvarez, E., Carneiro, B.A., Mager, R., Barnhart, V., Murtomaki, E., He, Y., Cooper, Z.A., Tu, E., Linke, A., Fan, C., Zhou, D., Boyer Chammard, A., Paturel, C.L., Fraenkel, P.G., Powderly, J.

Source: In Immuno-Oncology and Technology December 2022 16 Supplement 1

OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update

Authors: Spigel, D.R. ¹, Ahn, M.-J. ², Majem, M. ³, Medina Rodríguez, L. ⁴, Lee, K.H. ⁵, Carcereny, E. ⁶, Hernández, A.A. ⁷, Insa, A. ⁸, Cho, E.K. ⁹, Besse, B. ¹⁰, Rha, S.Y. ¹¹, Weiss, J. ¹², D'Arcangelo, M. ¹³, Im, S.-A. ¹⁴, Kim, S.-W. ¹⁵, Carneiro, B.A. ¹⁶, Gadgeel, S.M. ¹⁷, Mitchell, P. ¹⁸, Asare, J.M. ¹⁹, Gainer, S.D. ¹⁹, Achour, I. ¹⁹, Subramaniam, D.S. ¹⁹, Felip, E. ²⁰

Source: In Journal of Thoracic Oncology October 2024 19(10) Supplement:S33-S34

619MO Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)

Authors: Carneiro, B.A., Rosen, E., Fontana, E., Lee, E.K., Mettu, N.B., Lheureux, S., Plummer, R., Silverman, I.M., Schonhoft, J.D., Yang, J., Gomez, G., Fei, K., Ulanet, D., Basciano, P.A., Yap, T.A., Hoejgaard, M.

Source: In Annals of Oncology September 2024 35 Supplement 2:S496-S496

2281P Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)

Authors: Wei, S., Krause, H., Wright, K., Schaefer, I-M., Odintsov, I., Phan, M., Ayanambakkam, A., Chen, W.R., Liu, K., Farrell, A., Soror, N., Elliott, A., Barata, P., Heath, E., Carneiro, B.A., Nabhan, C., Chen, A., Rosenberg, A.E., Geynisman, D., Naqash, A-R.

Source: In Annals of Oncology October 2023 34 Supplement 2:S1169-S1170

1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)

Authors: Voss, M.H., Garmezy, B., Kim, S.H., Maroto Rey, J.P., Mansinho, A.B., Rodriguez-Vida, A., Oliveira, J., van Dongen, M., Rodríguez, L. Medina, Negrier, S., Tran, B., Carneiro, B.A., Alvarez, E. Castanon, Rha, S.Y., Wang, Y., Gainer, S.D., Tang, Z., Achour, I., Asare, J.M., Albiges, L.

Source: In Annals of Oncology October 2023 34 Supplement 2:S1012-S1012

1188P Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)

Authors: Crymes, A., Evans, M.G., Elliott, A., Lozada, J.R., Carneiro, E., Carneiro, B.A., Lou, E., Soares, H.P., Antonarakis, E.S., Ryan, C.J., Nabhan, C., Marks, J., Beltran, H., Hwang, J.H.

Source: In Annals of Oncology October 2023 34 Supplement 2:S703-S704

1771P Genomic characteristics and clinical outcomes of HRAS-mutated urothelial bladder cancer

Authors: Ocejo Gallegos, J.A., Rodriguez, E., Trabolsi, A., Kareff, S., Yin, J., Walker, P., El-Deiry, W., Carneiro, B.A., Nabhan, C., Lopes, G., Merchan, J.

Source: In Annals of Oncology September 2022 33 Supplement 7:S1347-S1347

1185TiP First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors

Authors: Rotow, J., Yoh, K., Powderly, J.D., Shimizu, T., Perets, R., Paz-Ares, L., Phillips, A., Souers, A., Ansell, P.J., Jin, J., Badawi, M., Saab, R., Morrison-Thiele, G., Jeffries, S., Neagu Aristide, M.R., Carneiro, B.A., Papadopoulos, K.P.

Source: In Annals of Oncology September 2022 33 Supplement 7:S1090-S1090

P.0899 Pilot study of the neurocognitive effects of arketamine in treatment-resistant depression and bipolar depression

Authors: Souza-Marques, B., Santos-Lima, C., Vieira, F., Bandeira, I.D., Leal, G.C., Silva, S.S., Mello, R.P., Carneiro, B.A., Jesus-Nunes, A.P., Caliman-Fontes, A.T., Beanes, G., Lacerda, A.L.T., Sampaio, A.S., Quarantini, L.C.

Source: In European Neuropsychopharmacology December 2021 53 Supplement 1:S660-S661

632P Differential transcriptomic profiling of BCL2-related genes in primary tumor (PT) and metastatic sites (MS) of prostate cancer (PCa)

Authors: Carneiro, B.A., Yin, J., Soliman, L., De Souza, A., Golijanin, D., Mega, A., Coelho Barata, P.M., Gulati, S., Wei, S., Geynisman, D., Magee, D., Korn, W.M., Abuali, I., Heath, E., Ryan, C.J., Bertone, P., El-Deiry, W.S.

Source: In Annals of Oncology September 2021 32 Supplement 5:S665-S665

1075TiP MEDI1191, a novel IL-12 mRNA therapy for intratumoral (IT) injection for advanced solid tumours

Authors: Marron, T., Subbiah, V., Hamid, O., Goel, S., Hellmann, M.D., Carneiro, B.A., Pate, S.P., de Vries, E., Luheshi, N., Hernández, A. Gascó

Source: In Annals of Oncology September 2020 31 Supplement 4:S730-S730

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours

Authors: Powderly, J., Bendell, J.C., Carneiro, B.A., Italiano, A., Mercadé, T. Macarulla, Alvarez, E. Castanon, Imbimbo, M., Massard, C., Mueller, N., Gascó -Hernandez, A.

Source: In Annals of Oncology September 2020 31 Supplement 4:S728-S729

1201P - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)

Authors: Cho, M. ¹, Bendell, J.C. ², Han, S.-W. ³, Naidoo, J. ⁴, Lieu, C. ⁵, Carneiro, B.A. ⁶, Varga, E. ⁷, Li, X. ⁸, Kourtesis, P. ⁸, Abdullah, S.E. ⁸, Patel, S. ⁹

Source: In Annals of Oncology October 2019 30 Supplement 5:v490-v491